An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to assess the safety and efficacy of repeated
subcutaneous (SC) injections of KRN23 in adult subjects with X-Linked Hypophosphatemia (XLH).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Kyowa Hakko Kirin Pharma, Inc.
Collaborators:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.